<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03511521</url>
  </required_header>
  <id_info>
    <org_study_id>STU00207079</org_study_id>
    <nct_id>NCT03511521</nct_id>
  </id_info>
  <brief_title>Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia</brief_title>
  <official_title>Use of Neutral Protamine Hagedorn (NPH) Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glucocorticoids are known to cause an increase in insulin resistance, leading to
      hyperglycemia, in both diabetic and non-diabetic patients. In both the inpatient and
      outpatient setting, steroids are used for their anti-inflammatory property to treat a variety
      of conditions. There is a paucity of information regarding the best way to treat
      steroid-induced hyperglycemia. In this study we will compare (1) the addition of NPH insulin,
      an intermediate-acting insulin, given at the time of steroid administration to the patient's
      standard basal/bolus insulin to (2) modification of the standard basal-bolus insulin regimen
      which will consist primarily increasing the prandial doses at lunch and supper in order to
      determine which regimen is superior for glycemic control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inpatients who will receive single daily doses of prednisone or methylprednisolone for
      treatment of their underlying condition and who become hyperglycemic will be eligible.
      Subjects will be randomized in a 1:1 fashion to one of two arms: (1) to their standard basal
      bolus insulin the addition of NPH insulin given at the time of the steroid adminstration,
      adjusting the dose based on the dose of steroid; (2) an increase in the basal and prandial
      bolus insulin doses based on the dose of steroid. Glycemic control and the incidence of
      hypoglycemia will be assessed over the first 3 days after initiating these insulin regimens.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 26, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients receiving single dose steroids who become hyperglycemic will be randomized to two treatment arms in a parallel design: (1) NPH added to basal/bolus insulin; (2) increase in doses of basal and bolus insulin</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic control</measure>
    <time_frame>3 days</time_frame>
    <description>mean of 4 glucose levels per day (premeal and bedtime) for each group for first 3 days after intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportions of glucose values within therapeutic range</measure>
    <time_frame>3 days</time_frame>
    <description>Proportions of the 12 glucose values (premeal and bedtime for 3 days) within the therapeutic targets of 80 - 140 and 80 - 180 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of glucose values within the hypoglycemic range</measure>
    <time_frame>3 days</time_frame>
    <description>Proportions of the 12 glucose values (premeal and bedtime for 3 days) less than 70 mg/dL and 54 mg/dL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hyperglycemia Steroid-induced</condition>
  <condition>Insulin Resistance, Diabetes</condition>
  <arm_group>
    <arm_group_label>NPH Insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NPH will be given at the time of steroid administration to the patient in addition to standard basal/bolus insulin the patient may be receiving in the following doses:
Prednisone Dose (mg/day) - NPH dose (Units): 10-20 mg/day - 1.2U (units)/mg; 21-40 mg/day - 0.6U/mg; 41-60 mg/day - 0.45U/mg; 61-80 mg/day - 0.3U/mg; &gt;80 mg/day - no additional NPH. Note that the amounts of NPH are added to each other for the various prednisone doses. For example, a dose of 75 mg/day of prednisone would come out to be (1.2U x 20mg = 24U) + (0.6U x 20mg = 12U) + (0.45U x 20mg = 9U) + 0.3U x 15 mg = 4.5U) for a total of 24 + 12 + 9 + 4.5 = 49.5U of NPH for 75 mg of prednisone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basal/Bolus Insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Basal insulin (glargine) and Bolus insulin (insulin aspart) will be increased (doses given in U [units]/kg) according to the Prednisone dose (mg/day) as follows:
Prednisone Dose (mg/day) - doses of insulin (U/kg): Prednisone 0 mg - Glargine 0.25U/kg, Bkfst Aspart 0.08U/kg, Lunch Aspart 0.08U/kg, Dinner Aspart - 0.08U/kg; Prednisone 10-20 mg - Glargine 0.25U/kg, Bkfst Aspart 0.1U/kg, Lunch Aspart 0.15U/kg, Dinner Aspart - 0.2U/kg; Prednisone 21-40 mg - Glargine 0.25U/kg, Bkfst Aspart 0.1U/kg, Lunch Aspart 0.2U/kg, Dinner Aspart - 0.25U/kg; Prednisone 41-60 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.25U/kg, Dinner Aspart - 0.30U/kg; Prednisone 61-80 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.30U/kg, Dinner Aspart - 0.35U/kg; Prednisone &gt;80 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.35U/kg, Dinner Aspart - 0.40U/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPH Insulin</intervention_name>
    <description>Intermediate acting insulin</description>
    <arm_group_label>NPH Insulin</arm_group_label>
    <other_name>Humulin N</other_name>
    <other_name>Novolin N</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glargine</intervention_name>
    <description>basal insulin</description>
    <arm_group_label>NPH Insulin</arm_group_label>
    <arm_group_label>Basal/Bolus Insulin</arm_group_label>
    <other_name>Lantus</other_name>
    <other_name>Basaglar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart</intervention_name>
    <description>prandial insulin</description>
    <arm_group_label>NPH Insulin</arm_group_label>
    <arm_group_label>Basal/Bolus Insulin</arm_group_label>
    <other_name>Novolog</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients receiving once daily dosing of methylprednisolone or prednisone in a dose of
             10 mg/day or greater

          -  Hyperglycemic (Glucose level &gt; 126 mg/dL)

          -  Diabetic and nondiabetic patients

          -  Expected duration of hospital stay and time on steroids &gt;= 3 days

          -  Patient of appropriate caregiver able to give Informed Consent

        Exclusion Criteria:

          -  Patients with 2 or more doses of methylprednisolone/prednisone per day

          -  Steroids other than methylprednisolone or prednisone

          -  Pregnancy

          -  estimated glomerular filtration rate (eGFR) &lt; 45 ml/min/1.73m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Molitch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University Feinberg School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark E Molitch, MD</last_name>
    <phone>312 503-4130</phone>
    <email>molitch@northwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amisha Wallia, MD</last_name>
    <phone>312 503-2756</phone>
    <email>a-wallia@northwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Smita Kumar, MD</last_name>
      <phone>312-695-1535</phone>
      <email>smita.kumar@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Smita Kumar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathleen Schmidt, APRN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tiffany Grant, APRN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erica Tayaban, APRN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana Johnson Oakes, APRN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amisha Wallia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dhital SM, Shenker Y, Meredith M, Davis DB. A retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone-associated diabetes mellitus in hospitalized patients. Endocr Pract. 2012 Sep-Oct;18(5):712-9. doi: 10.4158/EP11371.OR.</citation>
    <PMID>22784834</PMID>
  </results_reference>
  <results_reference>
    <citation>Ruiz de Adana MS, Colomo N, Maldonado-Araque C, Fontalba MI, Linares F, García-Torres F, Fernández R, Bautista C, Olveira G, de la Cruz JL, Rojo-Martínez G, Valdés S. Randomized clinical trial of the efficacy and safety of insulin glargine vs. NPH insulin as basal insulin for the treatment of glucocorticoid induced hyperglycemia using continuous glucose monitoring in hospitalized patients with type 2 diabetes and respiratory disease. Diabetes Res Clin Pract. 2015 Nov;110(2):158-65. doi: 10.1016/j.diabres.2015.09.015. Epub 2015 Sep 30.</citation>
    <PMID>26474657</PMID>
  </results_reference>
  <results_reference>
    <citation>Radhakutty A, Stranks JL, Mangelsdorf BL, Drake SM, Roberts GW, Zimmermann AT, Stranks SN, Thompson CH, Burt MG. Treatment of prednisolone-induced hyperglycaemia in hospitalized patients: Insights from a randomized, controlled study. Diabetes Obes Metab. 2017 Apr;19(4):571-578. doi: 10.1111/dom.12859. Epub 2017 Feb 17.</citation>
    <PMID>27995731</PMID>
  </results_reference>
  <results_reference>
    <citation>Bevier WC, Zisser HC, Jovanovic L, Finan DA, Palerm CC, Seborg DE, Doyle FJ 3rd. Use of continuous glucose monitoring to estimate insulin requirements in patients with type 1 diabetes mellitus during a short course of prednisone. J Diabetes Sci Technol. 2008 Jul;2(4):578-83.</citation>
    <PMID>19885233</PMID>
  </results_reference>
  <results_reference>
    <citation>Seggelke SA, Gibbs J, Draznin B. Pilot study of using neutral protamine Hagedorn insulin to counteract the effect of methylprednisolone in hospitalized patients with diabetes. J Hosp Med. 2011 Mar;6(3):175-6. doi: 10.1002/jhm.874.</citation>
    <PMID>21387555</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2018</study_first_submitted>
  <study_first_submitted_qc>April 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2018</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>steroid</keyword>
  <keyword>prednisone</keyword>
  <keyword>methylprednisolone</keyword>
  <keyword>hyperglycemia</keyword>
  <keyword>insulin</keyword>
  <keyword>hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Isophane insulin, beef</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

